.jpg)
Being Positive SAVES LIVES
Magneto was established as part of Incentive, Peregrine Ventures' Incubator. Our focus is developing innovative thrombectomy solutions for the removal of blood clots in the vascular system.
TECHNOLOGY
The Magneto catheter features a dual-action solution: an ultra-flexible aspiration design with a larger bore for maximum aspiration power combined with electric fields that create an attraction with the target clot.
When voltage is applied, the negatively charged ions of the clot are bonded to the active positive electrode of the catheter, creating a strong magnetic type of grip. This allows for clot removal without damaging the endoluminal surface of the vessel while lessening the chance of distal embolization.
The fibrin content of a blood clot possesses high charge electrical density enabling strong adherence. Magneto's technology has been proven to be effective for all clot types - from acute- soft, red, Red Blood Cell-rich clots to chronic- firm, white, fibrin-rich clots. In-vitro tests have shown success in addressing a wide range of clot types with this proprietary technology.
Device activated in clot.
Device activated in blood.
CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use.
PULMONARY EMBOLISM (PE)
THE NEED FOR TREATMENT
A pulmonary embolism (PE) is a blood clot in the blood vessels of your lung. This happens when a clot in another part of your body (often your leg or arm) moves through the veins to your lung. A PE restricts blood flow to your lungs, lowers oxygen levels in your lungs and increases blood pressure in your pulmonary arteries. Without quick treatment, a pulmonary embolism can cause heart or lung damage and even death.
500,000 people in the US experience a pulmonary embolism each year,. out of which, 250,000 are high/Intermediate risk patients that can benefit from catheter-based treatment.
PE is the 3rd leading cause of cardiovascular death, and a leading cause of preventable deaths in hospital.
Currently available catheter-based treatments are:
-
Catheter directed thrombolysis
-
Aspiration thrombectomy
-
Mechanical thrombectomy
OUR SOLUTION
The eTrieve™ PE kit is custom-designed for the pulmonary arteries. Using eFlex™ ultra-flexible large bore aspiration catheter, together with the eTrieve™ Catheter with our proprietary electric attachment technology, the system can remove both proximal and distal emboli with minimal artery interaction and less fragmentation.
BENEFITS
Single session procedure
Eliminate the need for thrombolytics drugs and an ICU stay
No capital equipment required
Lessening the chance of distal embolization
Minimizing damage to the endoluminal surface of the vessel
PRODUCT PICTURES
CLINICAL DATA
The company has demonstrated the safety and efficacy of its eTrieve PE Kit with its successful first-in-human (FIH) study. The results showed a significant reduction in right ventricular to left ventricular diameter (RV/LV) ratio and alleviation of symptoms associated with PE.
Overall clinical results
Users testimonials
Prof. Piotr Musialek, Jagiellonian University, John Paul II Hospital, Krakow, Poland
Magneto provides increased and high-risk PE patients with a unique opportunity to have their large clots blocking the arteries in the lungs effectively removed — using a combination of large-diameter vacuum/cleaner with electro- mechanical thrombus extraction, allowing an immediate resolution of dyspnea and swift recovery of the cardio-respiratory system.
Prof. Aleksander Araszkiewicz, Poznan University of Medical Sciences, Poznan, Poland
Very promising technique, easily applicable.
Prof. Asger Andersen, Aarhus University, Aarhus, Denmark
Large bore aspiration of central clots with possibility to retrieve segmental clots with the eTrieve catheter, optimizes the possibility for complete pulmonary revascularization in acute PE.
The company is planning an international clinical study that will support product marketing approvals worldwide.
CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use.
ISCHEMIC STROKE
THE NEED FOR TREATMENT
A stroke occurs when blood flow to an area of brain is cut off. When this happens, brain cells are deprived of oxygen and begin to die. When brain cells die during a stroke, abilities controlled by that area of the brain such as memory and muscle control are lost.
Mechanical thrombectomy devices comprise a wide array of endovascular tools cleared for removing thrombi from the neurovasculature in acute ischemic stroke patients.
Today most of the devices are based on mechanical mechanisms that disrupt the clot and apply a strong outward radial force on both thrombus and vessel wall. The clot is then dragged along the vessel to an aspiration catheter positioned proximally. Alternatively, a direct contact aspiration approach may be used, where an aspiration catheter is brought into contact with the clot and suction forces are generated on the proximal end of the thrombus (potentially losing parts of it). Current technologies are limited by the size of the vessel and the clot properties, and an optimal solution of removing the entirety of the clot with minimum number of attempts and disruptions is still desired.
OUR SOLUTION
The Magneto eTrieve™ Microcatheter is custom designed for the neurovascular arteries. Using Magneto proprietary technology, the catheter can remove both proximal and distal emboli with minimal artery interaction and less fragmentation.
BENEFITS
Strong Attachment forces
Faster treatment with fewer devices, only microcatheter with no additional retriever
Minimal device\artery interaction, more distal vessels accessible
Less fragmentation
CLINICAL DATA
A First-in-Human clinical study is on-going.
CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use.
PIPELINE
Magneto's technology can be applied in multiple therapeutic areas. Among them, current developments are ongoing in the treatment of stroke, Deep Vein Thrombosis (DVT) and the removal of clots from the arterial system.
MANAGEMENT TEAM
Benny Dilmoney
CEO
Rafi Benary
Co-founder
and CTO
Yuval Taff
Co-founder
and CSO
Tami Abudi
VP Clinical &
Regulatory Affairs
